According to Nuvama, the increased competitive intensity following this approval is negative for Cipla, as it raises the risk ...

The shares of Cipla dropped nearly 2 percent to its day's high on January 13 after the US FDA granted its final approval to ...

Mylan N.V. (NASDAQ, TASE: MYL) today announced that its abbreviated new drug application (ANDA) for fluticasone propionate 100, 250, 500 mcg and salmeterol 50 mcg inhalation powder has been accepted ...

1. Wixela Inhub is Mylan’s generic version of Advair, an asthma treatment made by GlaxoSmithKline. 2. Tosymra is a sumatriptan nasal spray used to treat migraines in adults. 3. Imbruvica in ...

Pharmaceuticals giant GlaxoSmithKline has come under pressure after the US drug regulator said it may approve a generic version of GSK's biggest selling product next year. The US Food and Drug ...

GlaxoSmithKline gains 2.7 percent after Novartis hands back U.S. rights to a drug widely thought to be a generic copy of its blockbuster Advair, reducing the threat of cheap copies of the lung drug in ...